Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/1939
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorOLIVEIRA, C. P. M. S.-
dc.contributor.authorKAPPEL, C. R.-
dc.contributor.authorSIQUEIRA, E. R.-
dc.contributor.authorLIMA, V. M. R.-
dc.contributor.authorSTEFANO, J. T.-
dc.contributor.authorMICHALCZUK, M. T.-
dc.contributor.authorMARINI, S. S.-
dc.contributor.authorBARBEIRO, H. V.-
dc.contributor.authorSORIANO, F. G.-
dc.contributor.authorCARRILHO, F. J.-
dc.contributor.authorPEREIRA, L. M. M. B.-
dc.contributor.authorALVARES-DA-SILVA, M. R.-
dc.date.accessioned2013-09-23T16:39:10Z-
dc.date.available2013-09-23T16:39:10Z-
dc.date.issued2013-
dc.identifier.citationINTERNATIONAL JOURNAL OF CARDIOLOGY, v.164, n.2, p.221-226, 2013-
dc.identifier.issn0167-5273-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/1939-
dc.description.abstractThe role of hepatitis C virus (HCV) in the pathogenesis of atherosclerosis and cardiovascular events is unclear. The aim of this study was to evaluate the direct effect of HCV on cardiovascular risk and correlate it with pro and anti-inflammatory cytokines in patients with HCV. HCV monoinfected patients, genotype 1, naive, non-obese (BMI<30) and non-diabetics were included and compared to controls (blood donors). Patients with prior diagnosis of cardiovascular diseases, hypertension, chronic renal failure, cancer and chronic use of lipid-lowering drugs or immunosuppressants were excluded. Age, BMI, systolic blood pressure (SBP) and diastolic (DBP), fasting glucose and lipid levels were determined. Serum cytokines (IL-6, IL-10 and TNF-alpha) and Framingham score were also evaluated. 62 HCV patients, 34 (54.8%) were males and none of them was smoking. The Framingham scores (median and 25th and 75th percentiles) were 12% (6.5-14%), showing an intermediate cardiovascular risk in patients with HCV. There was significant direct correlation between Framingham and total cholesterol (p=0.043) and DBP (p=0.007). HDL-C (p=0.002) was inversely correlated with the Framingham score. HCV patients had higher levels of proinflammatory cytokines (IL-6 and TNF-alpha) compared to controls (p<0.0001) and the relation of proinflammatory/anti-inflammatory TNF-alpha/IL10 and IL-6/IL10 were higher in HCV patients (p<0.01). The Framingham score was directly correlated to IL-6 and TNF-alpha, but differences were not statistically significant. Patients with HCV monoinfected, nonobese, naive and non diabetic have an intermediate cardiovascular risk, as measured by the Framingham score and high levels of proinflammatory cytokines (IL-6 and TNF).-
dc.language.isoeng-
dc.publisherELSEVIER IRELAND LTD-
dc.relation.ispartofInternational Journal of Cardiology-
dc.rightsrestrictedAccess-
dc.subjectHepatitis C virus-
dc.subjectCardiovascular risk-
dc.subjectFramingham Score-
dc.subjectPro-inflammatory cytokines-
dc.subject.otherinsulin-resistance-
dc.subject.othercells-
dc.subject.otheratherosclerosis-
dc.subject.otherassociation-
dc.subject.otherexpression-
dc.subject.othersteatosis-
dc.subject.otherdisease-
dc.subject.otherinterleukin-10-
dc.subject.otherseropositivity-
dc.subject.othercholesterol-
dc.titleEffects of Hepatitis C virus on cardiovascular risk in infected patients: A comparative study-
dc.typearticle-
dc.rights.holderCopyright ELSEVIER IRELAND LTD-
dc.identifier.doi10.1016/j.ijcard.2011.07.016-
dc.identifier.pmid21784542-
dc.subject.wosCardiac & Cardiovascular Systems-
dc.type.categoryoriginal article-
dc.type.versionpublishedVersion-
hcfmusp.author.externalKAPPEL, C. R.:Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Sch Med, Div Gastroenterol, Porto Alegre, RS, Brazil-
hcfmusp.author.externalSIQUEIRA, E. R.:Liver Inst Pernambuco, Recife, PE, Brazil-
hcfmusp.author.externalMICHALCZUK, M. T.:Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Sch Med, Div Gastroenterol, Porto Alegre, RS, Brazil-
hcfmusp.author.externalMARINI, S. S.:Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Sch Med, Div Gastroenterol, Porto Alegre, RS, Brazil-
hcfmusp.author.externalPEREIRA, L. M. M. B.:Liver Inst Pernambuco, Recife, PE, Brazil-
hcfmusp.author.externalALVARES-DA-SILVA, M. R.:Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Sch Med, Div Gastroenterol, Porto Alegre, RS, Brazil-
hcfmusp.description.beginpage221-
hcfmusp.description.endpage226-
hcfmusp.description.issue2-
hcfmusp.description.volume164-
hcfmusp.origemWOS-
hcfmusp.origem.id2-s2.0-84875217762-
hcfmusp.origem.idWOS:000316599200018-
hcfmusp.publisher.cityCLARE-
hcfmusp.publisher.countryIRELAND-
hcfmusp.relation.referenceAbbas Z, 2003, J Pak Med Assoc, V53, P59-
hcfmusp.relation.referenceALTER MJ, 1995, SEMIN LIVER DIS, V15, P5, DOI 10.1055/s-2007-1007259-
hcfmusp.relation.referenceANDERSON C, 1991, NATURE, V353, P289-
hcfmusp.relation.referenceANDERSON KM, 1991, CIRCULATION, V83, P356-
hcfmusp.relation.referenceArmstrong GL, 2006, ANN INTERN MED, V144, P705-
hcfmusp.relation.referenceBoddi Maria, 2007, Dig Liver Dis, V39 Suppl 1, pS55, DOI 10.1016/S1590-8658(07)80012-0-
hcfmusp.relation.referenceBrown PMJ, 2001, CLIN BIOCHEM, V34, P167, DOI 10.1016/S0009-9120(01)00210-7-
hcfmusp.relation.referenceChen Y, 2007, AM J PHYSIOL-RENAL, V293, P680-
hcfmusp.relation.referenceClement S, 2009, VIRUSES-BASEL, V1, P126, DOI 10.3390/v1020126-
hcfmusp.relation.referenceCorey KE, 2009, HEPATOLOGY, V50, P1030, DOI 10.1002/hep.23219-
hcfmusp.relation.referenceDanesh J, 1997, LANCET, V350, P430, DOI 10.1016/S0140-6736(97)03079-1-
hcfmusp.relation.referencede Waal MR, 1991, J EXP MED, V174, P915, DOI 10.1084/JEM.174.4.915-
hcfmusp.relation.referencede Waal M.R., 1991, J EXP MED, V174, P1209-
hcfmusp.relation.referenceFartoux L, 2005, GUT, V54, P1003, DOI 10.1136/gut.2004.050302-
hcfmusp.relation.referenceFernandez-Real JM, 1999, DIABETOLOGIA, V42, P1367, DOI 10.1007/s001250051451-
hcfmusp.relation.referenceFIORENTINO DF, 1991, J IMMUNOL, V146, P3444-
hcfmusp.relation.referenceFloris-Moore M, 2007, AIDS PATIENT CARE ST, V21, P479, DOI 10.1089/apc.2006.0150-
hcfmusp.relation.referenceFreiberg MS, 2007, AIDS, V21, P193, DOI 10.1097/QAD.0b013e3280118a0d-
hcfmusp.relation.referenceFukui M, 2003, JAMA-J AM MED ASSOC, V289, P1245, DOI 10.1001/jama.289.10.1245-b-
hcfmusp.relation.referenceGruady SM, 2004, CIRCULATION, V109, P551-
hcfmusp.relation.referenceGuiltinan AM, 2008, AM J EPIDEMIOL, V167, P743, DOI 10.1093/aje/kwm370-
hcfmusp.relation.referenceHansson GK, 2001, ARTERIOSCL THROM VAS, V21, P1876, DOI 10.1161/hq1201.100220-
hcfmusp.relation.referenceIshizaka N, 2002, LANCET, V359, P133, DOI 10.1016/S0140-6736(02)07339-7-
hcfmusp.relation.referenceLecube A, 2006, DIABETES CARE, V29, P1096, DOI 10.2337/dc05-2509-
hcfmusp.relation.referenceLlorente L, 1996, J HEPATOL, V24, P555, DOI 10.1016/S0168-8278(96)80140-1-
hcfmusp.relation.referenceMaggi G, 1996, ITAL J GASTROENTEROL, V28, P436-
hcfmusp.relation.referenceMarzouk D, 2007, GUT, V56, P1105, DOI 10.1136/gut.2006.091983-
hcfmusp.relation.referenceMilner KL, 2010, GASTROENTEROLOGY, V138, P932, DOI 10.1053/j.gastro.2009.11.050-
hcfmusp.relation.referenceMostafa A, 2010, GUT, V59, P1135, DOI 10.1136/gut.2009.202317-
hcfmusp.relation.referenceNegro F, 2009, J VIRAL HEPATITIS, V16, P681, DOI 10.1111/j.1365-2893.2009.01186.x-
hcfmusp.relation.referencePersico M, 2007, HEPATOLOGY, V46, P1009, DOI 10.1002/hep.21782-
hcfmusp.relation.referenceRuan XZ, 2003, J AM SOC NEPHROL, V14, P593, DOI 10.1097/01.ASN.0000050414.52908.DA-
hcfmusp.relation.referenceSyed GH, 2009, TRENDS ENDOCRIN MET, V21, P33-
hcfmusp.relation.referenceTsui JI, 2009, J CARD FAIL, V15, P451, DOI [10.1016/j.cardfail.2008.12.003, 10.1016/j.cardfail.2009.12.003]-
hcfmusp.relation.referenceTsuruma T, 1998, CELL IMMUNOL, V184, P121, DOI 10.1006/cimm.1998.1266-
hcfmusp.relation.referenceVassalle C, 2004, HEART, V90, P565, DOI 10.1136/hrt.2003.018937-
hcfmusp.relation.referenceWanner C, 2005, NEW ENGL J MED, V353, P238, DOI 10.1056/NEJMoa043545-
hcfmusp.relation.referenceYue FY, 1997, INT J CANCER, V71, P630, DOI 10.1002/(SICI)1097-0215(19970516)71:4<630::AID-IJC20>3.0.CO;2-E-
hcfmusp.relation.referenceZeller JC, 1999, J IMMUNOL, V163, P3684-
dc.description.indexMEDLINE-
hcfmusp.citation.scopus72-
hcfmusp.scopus.lastupdate2024-03-08-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MCM
Departamento de Clínica Médica - FM/MCM

Artigos e Materiais de Revistas Científicas - FM/MGT
Departamento de Gastroenterologia - FM/MGT

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - LIM/07
LIM/07 - Laboratório de Gastroenterologia Clínica e Experimental

Artigos e Materiais de Revistas Científicas - LIM/51
LIM/51 - Laboratório de Emergências Clínicas

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar


Files in This Item:
File Description SizeFormat 
art_OLIVEIRA_Effects_of_Hepatitis_C_virus_on_cardiovascular_risk_2013.PDF
  Restricted Access
publishedVersion (English)605.97 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.